Please assess the completion status of the following clinical trial:

Trial Title: Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women with a diagnosis diagnosis of Impaired Glucose Tolerance i.e. fasting plasma glucose less than or equal to 125 mg/dl, 2 hour post 75 gram oral glucose tolerance test (OGTT) plasma glucose between 140-199 mg/dl, glycosylated hemoglobin A1c (HbA1c) less than 6.5% as per American Diabetes Association (ADA) criteria.~* Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.~Exclusion Criteria:~* Patients must not be on anti-diabetes therapy for treatment of Impaired Glucose Tolerance (IGT) and must have a fasting plasma glucose concentration less or equal to 125 mg/dl.~* Type 1 or Type 2 diabetes mellitus (fasting plasma glucose greater than 125 mg/dl).~* Patients must not be on or have received metformin, thiazolidinediones, sulfonylureas, DPP IV inhibitor, or exenatide/liraglutide treatment for treatment of IGT at any time. Patients must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications such as hormone replacement therapy with known adverse effects on glucose tolerance levels. Patients taking systemic glucocorticoids will also be excluded.~* Subjects with a history of clinically significant heart disease, peripheral vascular disease, or pulmonary disease.~* Subjects must have a Body Mass Index between 30-35 kg/m2 and stable body weight.~* Subjects must not have clinically significant liver disease (aspartate aminotransferase (AST) \< 2.5 times upper limit of normal, Alanine transaminase (ALT) \< 2.5 times upper limit of normal, Alkaline phosphatase\< 2.5 times upper limit of normal), kidney disease (Serum creatinine \< 1.5 mg/dl in men and 1.4 mg/dl in women) or significant anemia (Hematocrit \< 34 vol%).~* Subjects with a history of any serious hypersensitivity reaction to saxagliptin or a dipeptidyl peptidase 4 (DPP-IV) inhibitor.~* Concomitant treatment with systemic cytochrome P450 3A4 inducers.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 5 mg orally daily for 6 months
- Saxagliptin (Type: EXPERIMENTAL): Saxagliptin 5 mg orally daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).